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Abstract (200 words):  
Background: Age-related macular degeneration (AMD) is responsible for half of registered visual 
impairment in the UK. The Royal College of Ophthalmologists recommends providing guidance to 
people with AMD regarding smoking, diet, and nutritional supplements. The aim of this study was to 
investigate lifestyle advice recalled by patients with neovascular AMD (nAMD).  
Methods: The study took place at a UK hospital outpatients’ clinic. Eligible patients with unilateral 
nAMD were presented with a survey about lifestyle advice provision.   
Results: Of 248 respondents, only 39.9% remembered receiving advice regarding diet at the hospital. 
Only 24.2% of respondents recalled receiving advice regarding nutritional supplements, and only 
19.8% of respondents started taking daily supplements as a result of their AMD. The most prevalent 
reason for not taking supplements amongst those advised to do so was lack of understanding of how 
it would help their eyes. Nearly 13% of the sample reported currently smoking, 53.1% of which 
reported that they were advised to stop smoking when diagnosed with AMD. 
Conclusion: The findings suggest that it would be beneficial to review the provision of lifestyle advice 
to patients attending AMD outpatients’ clinics, and to consider whether advice is being provided in 
an optimal format for later recall.  
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INTRODUCTION 
Age Related Macular Degeneration (AMD) is a degenerative condition of the central retina which is 
responsible for nearly 50% of certified sight impairment and severe sight impairment in the United 
Kingdom (UK).1 Late AMD may manifest in two ways. Neovascular AMD (nAMD) is associated with a 
rapid visual loss associated with the growth of fragile new blood vessels beneath the retina, whilst 
geographic atrophy (GA) results in an insidious loss of central vision.2 Owen et al (2012) estimated a 
prevalence of late AMD in the UK of 4.8% of people aged over 65 years and 12.2% of people aged 
over 80 years.3 The progressive loss of visual function attributable to AMD can be debilitating, 
resulting in reduced ability to carry out activities of daily living,4 problems with social engagement,5 
and a markedly increased risk of suffering from depressive symptoms.6-8 In addition to the impact of 
late AMD on the individual, it also has substantial economic implications at a societal level. The costs 
incurred by late AMD not only encompass treatment for nAMD, but also indirect costs such as social 
care, hospital treatment for falls, management of depressive symptoms, and residential care.9,10  
The medical interventions which are currently approved by the National Institute for Health and 
Clinical Excellence (NICE) for the treatment of AMD are only effective in treating the neovascular 
form of the disease.11,12 However, epidemiological studies have identified numerous candidate 
modifiable risk factors for AMD.13,14 Smoking is considered to be the strongest modifiable risk factor 
for AMD,13 whereby smokers have been reported to have a four-fold increased risk of developing 
late AMD compared to non-smokers.15 The risk of AMD reduces back to that of a never-smoker 
within 10 years of quitting.16 The Royal College of Ophthalmologists Guidelines are therefore to 
advise all patients with AMD to stop smoking.17  
Largely based on observational studies, certain diets have been proposed as being protective against 
AMD onset or progression, including a diet rich in omega-3 fatty acids, antioxidant vitamins, 
minerals, and carotenoids lutein and zeaxanthin.18,19 Although systematic reviews concluded that 
there is currently insufficient evidence to conclusively support a protective role of dietary 
antioxidant intake and omega-3 fatty acids,20,21 the guidance of the Royal College of 
Ophthalmologists is based on the premise that a diet rich in fruit and vegetables, oily fish and 
sources of lutein and zeaxanthin is unlikely to be harmful and may be beneficial.17  
There is stronger evidence to support the recommendation of nutritional supplements. The Age 
Related Eye Disease Study (AREDS) reported a 25% reduction in 5-year risk of AMD progression in 
patients with intermediate or unilateral late AMD on taking a supplement with high doses of beta-
carotene, vitamins C and E, and minerals zinc and copper.22 AREDS 2 found no additional benefit 
from adding lutein and zeaxanthin or omega-3 to the supplement in well-nourished populations.23 
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However, by substituting beta-carotene for lutein and zeaxanthin, the formula becomes accessible 
to smokers.24 The Royal College of Ophthalmologists guidelines recommend prescribing supplements 
based on the AREDS formulae in order to reduce risk of progression in those patients with 
intermediate AMD or unilateral late AMD, as long as there are no contra-indications.17  
Despite the robust evidence to support the provision of lifestyle modification advice to people with 
AMD, a recent survey of optometrists and ophthalmologists suggested that clinicians are not 
universally providing the recommended education to patients.25 The primary aim of this study was to 
investigate the lifestyle advice which patients attending a hospital outpatient clinic with a diagnosis 
of unilateral neovascular AMD (nAMD) recalled receiving from their hospital eyecare provider. A 
secondary aim was to investigate their self-reported compliance to advice given and, if appropriate, 
reasons for non-compliance.  
METHODS 
This cross-sectional survey-based study took place in the outpatients’ Eye Department of a hospital 
in Yorkshire, UK between June and November 2015. Ethical approval was obtained from the local 
NHS Trust Clinical Governance Committee and City, University of London Research Ethics 
Committee. Each survey had an information sheet appended, and completion of the survey 
indicated provision of consent to participate. The study conformed to the tenets of the Declaration 
of Helsinki. 
Survey 
An anonymous, written, self-report survey included questions that reflect current evidence-based 
AMD professional guidelines.17 The survey, produced in large print, comprised a tick box format 
including 20 closed questions with spaces to elaborate on answers (see Appendix 1). Participants 
were encouraged to tick all responses that applied. In order to validate the response options of the 
survey, 10 participants completed a series of verbal open questions encompassing the same topics 
as the closed item questions in the survey. The aim of this process was to ensure that the answer 
options on the survey broadly matched the range of responses given.  
Recruitment 
Patients with diagnosed unilateral nAMD were eligible for inclusion. For pragmatic reasons, an 
inability to read or understand the survey was an exclusion criterion. Recruitment took place 
through the direct approach of potential respondents by a nurse, while the patients were in the 
clinic waiting room. The nurse handed the survey to suitable patients along with the Participant 
Information Sheet. Based on the medical records, the diagnosis for each eye was recorded by the 
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nurse on the survey. The survey was completed whilst the patient was waiting to see an 
ophthalmologist and returned into a dedicated box.  
Statistical analysis 
As this was an exploratory study, no formal sample size calculations were performed. The sample 
size was determined by the response rate within the timeframe of recruitment. Graphical 
representations show the proportion of participants responding positively to each option. Where 
participants were given the option of ticking numerous response items, the sum of all percentage 
values exceed 100%. Values in the text and tables are presented as the mean ± standard deviation 
(SD) (normally distributed data), and as median ± interquartile range (IQR) (non-normally distributed 
data). A sub-analysis was carried out to determine the effect of demographic characteristics on 
participant responses (χ² test for categorical variables; independent samples T-test or Mann-
Whitney U test for continuous data). Statistical analyses were performed using SPSS for Windows 
(version 22.0, SPSS Inc., Chicago, USA). Data were tested for normality using the Shapiro Wilkes test. 
Statistical significance was accepted at the 95% confidence level (p<0.05).  
RESULTS 
Surveys were submitted by 248 participants (see Table 1). The response items in the survey 
encompassed the range of responses given in the open answer interview. No adjustments were 
made to the survey as result of this process.  
Dietary Recommendations 
The majority of respondents (n=149; 60.1%) reported receiving no advice regarding diet from their 
hospital eye care practitioner (Figure 1A). The most prevalent advice was to eat more green leafy 
vegetables (n=60; 80.0% of the n=75 who recalled that advice was given). A large number of 
participants (n=229; 92.3%) did not remember receiving dietary advice from any source outside of 
the hospital (Figure 1B). Of the participants that did receive recommendations from an outside 
source, the advice was similar to that given by their hospital eyecare provider, with 9 (47.3% of 
people who received external advice) being advised to eat more green leafy vegetables and different 
coloured fruit/vegetables. 
Only a minority (n=28; 11.3%) made a change to their diet as a result of their eyes (Figure 1C). The 
most common change was eating more green leafy and coloured vegetables (n=15, 53.6% of those 
who made a change). The reasons for not making any changes in diet are shown in Figure 1D. The 
most prevalent reason (n=109; 59.6% of those who made no change) was not being given any advice 
to do so, whilst 61 individuals (33.3%) felt that their diet was already sufficiently good. The median 
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age of those who had changed their diet (82 years IQR 11) was significantly higher than those who 
that had not (77 years IQR 14; Mann-Whitney; p=0.04). There was no significant difference in the 
proportion of people who made a change to their diet according to other demographic factors 
(p>0.05). 
  All Male Female 
General 
information 
(provided by all 
participants) 
Number 248 90 (36%) 158 (64%) 
Mean Age ± SD (years) 80 ± 8.1 80.5 ± 8.1 80.0 ± 8.1 
Age range (years) 57-99 57-94 58-99 
Living 
arrangements 
Lives alone 113 (45.6%) 33 (36.7%) 80 (50.6%) 
Lives with relative/ 
partner/ friend/ carer 
119 (48%) 55 (61.1%) 2 (2.2%) 
Lives in nursing home / 
assisted accommodation 
9 (3%) 64 (40.5%) 7 (4.4%) 
Not answered 7 (2.8%) 0 7 (4.4%) 
Time since 
diagnosis of 
AMD 
Within the last year 65 (26.2%) 18 (20%) 47 (29.7%) 
1-2 years ago 53 (21.4%) 22 (24.4%) 31 (19.6%) 
2-5 years ago 68 (27.4%) 25 (27.8%) 43 (27.2%) 
>5 years ago 58 (23.4%) 25 (27.8%) 33 (20.9%) 
Not answered 4 (1.6%) 0 4 (2.5%) 
Means of 
diagnosis 
High street optometrist 146 (58.9%) 47 (52.2%) 99 (62.7%) 
Hospital eye care 
practitioner 
65 (26.2%) 30 (33.3%) 35 (22.2%) 
GP 13 (5.2%) 8 (8.8%) 5 (3.2%) 
Diabetic Eye Screening 
Programme 
4 (1.6%) 0 
4 (2.5%) 
 
Not answered/couldn’t 
remember/’self-
diagnosed’ 
20 (8.1%) 5 (5.5%) 15 (9.5%) 
 
Table 1: Demographic characteristics of participants answering Q1-5 of survey (see Appendix 1) 
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Figure 1A-D. Bar charts showing breakdown of responses to questions 6-9 regarding diet (survey 
Appendix 1). Percentages relate to the proportion of respondents giving a certain response. Where 
multiple responses were given by individuals, the sum of percentages exceeds 100%.   
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Nutritional Supplements 
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Fig 2A-E. Responses to questions 10-14 regarding nutritional supplements (survey Appendix 1). 
Percentages relate to the proportion of respondents giving a certain response. Where multiple 
responses were given by individuals, the sum of percentages exceeds 100%. 
Nutritional supplements were only recommended to 60 respondents (24.2%) by the hospital eye 
care practitioners (Figure 2A). Twenty-three (9.3%) were given supplement advice from a source 
other than their hospital eye care practitioner; the most common outside advice came from 
optometrists (n=8; 3.2% of total respondents) (Figure 2B). Only 49 (19.8%) respondents started 
taking daily nutritional supplements as a result of their AMD (Figure 2C). The most prevalent reason 
for not taking supplements amongst those who had been advised to do so was that they did not 
understand how it would help their eyes (n=23; 13.4% of non-supplement takers) (Figure 2D). ICaps 
were the most widely used supplement (n=15; 30.6% of people who reporting taking supplements; 
Figure 2E). 
A significantly higher proportion of females than males reported taking supplements for their eyes 
(28.5% vs. 4.4%; χ² (1,N=211)=19.74, p<0.001). Whilst a higher proportion of women also reported 
receiving advice to take supplements from their hospital eyecare practitioner (28.5% vs. 16.7%; χ² (1, 
N=239)=4.20, p=0.04), there was no significant difference between genders regarding receiving 
advice from elsewhere (χ² (1,N=222)=0.77, p=0.82). The median age of people who reported taking 
supplements (77.5 years IQR 12.25) was significantly lower than those who did not (83 years IQR=10; 
Mann-Whitney, p=0.002). However, there was no significant effect of living arrangements (χ² 
(2,N=216)=2.51, p=0.29) or time since diagnosis (χ²(3,N=218)=1.87, p=0.60) on the proportion of 
people taking supplements. 
Smoking advice 
Nearly 13% of the total sample reported currently smoking (n=32), 41.9% used to smoke (n=104) and 
43.5% had never smoked (n=108; n=4). Of the current smokers, the average length of time smoked 
ranged from 24-82 years (median 60, IQR 16.5) and average number of cigarettes smoked per day 
ranged from 4-40 (median 10, IQR 13.3). The number of pack years smoked ranged between 8-75 
years (median 30, IQR 32.7).  Seventeen (53.1% of participants who were current smokers) reported 
that they were advised to stop smoking when diagnosed with AMD. The most common reason for 
not stopping was they enjoyed it too much (n=13, 40.6%). The median age of current smokers was 
significantly lower (76 years IQR 8.5) than those who were previous smokers (83 years IQR 9 years) 
or never smokers (82 years IQR 13.75; Mann-Whitney test, p=0.02).  
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Fig 3A-D. Responses to questions 15-19 regarding smoking (survey Appendix 1). Percentages relate 
to the proportion of respondents giving a certain response. Where multiple responses were given by 
individuals, the sum of percentages exceeds 100%. 
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DISCUSSION 
Main finding of this study  
The findings of this study indicate that the majority of patients attending an outpatient clinic for the 
treatment of nAMD had no recollection of being offered dietary advice (60.1%) or nutritional 
supplements (75.8%), and only around half of current smokers recalled being advised to stop 
smoking. This is contrary to the guidance from the UK professional body for ophthalmologists.17  
Given the robust findings of the AREDS(2) trials,22,23 that the appropriate nutritional supplements can 
delay disease progression in people with unilateral nAMD, it was surprising that nutritional 
supplements were only recommended to around a quarter of participants. The main reasons given 
by those who reported not taking nutritional supplements was that they were not advised to do so 
or that they did not understand how it would help their eyes. This highlights the need for enhanced 
education of the patients who would potentially benefit from supplementation. Unfortunately, 
whilst most participants were able to report the brand name of the supplements they took, they did 
not know which particular formula. This is relevant as many brands (e.g. Macushield and iCAPS) now 
produce a variety of formulae, only some of which are AREDS compliant. Further study is required to 
investigate whether patients are taking the most appropriate supplement.  
A greater proportion of females than males reported receiving advice to take supplements. The 
differential was even greater with respect to taking nutritional supplements (4% males vs. 29% 
females), suggesting a higher level of adherence to advice of women than men. Females did not 
show higher rates of compliance in terms of diet or smoking, indicating that the gender effect may 
be variable for different aspects of lifestyle advice. The effect of age was also variable, with older age 
being associated with greater adherence to dietary advice, but poorer adherence to supplement 
intake advice. Such demographic effects should be considered when targeting future educational 
materials to address lifestyle advice in people with AMD.  
Around 13% of the sample reported currently smoking, despite over half of them receiving advice to 
the contrary. The finding that smokers were significantly younger than non-smokers may reflect 
either the earlier age of onset of nAMD in smokers,26 or the reduced longevity.27 Given the robust 
evidence regarding the elevated AMD risk associated with cigarette smoking,26 the proportion of 
smokers given advice on cessation by their hospital eyecare provider would be expected to be 
substantially higher than 50%. 
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What is already known on this topic 
Lawrenson and Evans conducted a survey of 1468 UK optometrists (96.3%) and ophthalmologists 
(3.7%) through the Royal College of Ophthalmologists and the College of Optometrists.25 They 
reported that 68% of practitioners surveyed claimed to provide advice on diet to people with AMD 
whilst 93% of respondents recommended nutritional supplements to people with unilateral nAMD.25 
However, it is notable that the AREDS formula was recommended by only 13.5% of respondents in 
the scenario of a patient with unilateral AMD.25 Thus, whilst a greater proportion of clinicians 
purport to provide lifestyle advice to patients than would be expected from the results of our 
patient survey, there is evidence that a high proportion of clinicians may be unaware of best 
evidence based practice guidelines. 
A study of 158 people with AMD conducted through the Macular Society helpline in the UK reported 
that 30% had discussed nutritional supplements with their Ophthalmologist, and 15% with their 
Optometrist.28 This is broadly in line with the ~25% in this study. However, 79% of males and females 
interviewed in the previous study reported taking supplements (compared to 29% of females and 4% 
of males in the current study). This difference is likely to be attributable to the different sample – 
individuals associated with the Macular Society may be more motivated to make lifestyle changes 
than a cross-section of individuals attending an outpatients’ clinic.   
In accordance with this, literature suggests that, given appropriate advice provision, it is possible to 
achieve much higher rates of patient uptake of nutritional supplements than the 19.8% reported in 
this study. A survey in the Unites States of 332 patients with AMD reported that, of those eligible for 
AREDS type supplements, 61% were recorded as compliant.29 Similarly, a survey of individuals with 
AMD being treated at a vitreoretinal service in California reported that 98% of 92 patients 
remembered receiving advice about AREDS supplements; compliance was 88%.30 A questionnaire 
study of 163 outpatients diagnosed with AMD at Keio University Hospital, Japan, found that 35% 
used an AREDS type supplement under their Ophthalmologist’s instruction.31 Similarly to our study 
(58%), this equated to 62% of all of the participants who had received advice by their 
ophthalmologist to take the supplements. These findings reinforce the importance of advice 
provided by a trusted healthcare provider.  
The results of our survey tally with previous findings whereby only a third of clinician (mainly 
optometrist) respondents actively asked about a patient’s smoking history or engaged in providing 
advice on smoking cessation.25 In a previous study of 485 ophthalmologists, 35% claimed to regularly 
advise patients to quit smoking.32 The public is largely unaware of the association between smoking 
and the risk of AMD.33 Until this issue is addressed on a wider basis, the onus is on healthcare 
13 
 
professionals to address this deficit in public awareness. However, a study reporting an adherence 
rate above 80% to advice about nutritional factors in people with AMD found that none of the 
individuals who smoked followed advice to quit.30 This reported finding suggests that the message 
may be harder to convey than advice about dietary changes.  
What this study adds 
This is the first study to analyse self-reported data on lifestyle advice from patients with AMD in the 
UK tertiary care system. It provides important complementary information to previous data 
obtained from clinicians because, uniquely, this type of survey provides evidence about the advice 
retained by patients in a high-risk group for AMD progression, rather than just about the provision of 
advice. Much of the prior knowledge base in this field was generated by the key study by Lawrenson 
and Evans.25 Importantly, the data from this previous study of clinicians suggest a more 
comprehensive pattern of information provision to patients than the patient-reported results 
presented here. It is likely that this discrepancy reflects a mismatch between the provision of advice 
and the ability of patients to recall the advice at a later date. This is important as it indicates a need 
for services to focus not only ensuring that appropriate advice is given to patients, but also on how 
the educational material is provided to maximise patient recall and compliance. The discrepancy 
may also reflect the fact that clinicians responding to a survey provided through their professional 
body may over-represent those individuals inclined to be responsive to continuing education 
initiatives. 
Limitations of this study 
Overall, this study indicated that a lower proportion of patients is aware of receiving lifestyle advice 
than the proportion of practitioners who claim to be providing it.25,32 One limitation of this study was 
that, whilst participants were asked about nutritional supplement intake, insufficient details were 
obtained to determine whether the majority were taking AREDS or AREDS2 compliant formulae. 
Another limitation of this study was that the tick box format for the survey might have encouraged 
patients to present a more positive representation of their changes in lifestyle behaviour, in order to 
please their clinician, although the chance of this was minimised by the anonymity of the patient 
surveys. This effect would also be more likely to present an over-optimistic view of the lifestyle 
habits of the participants. The findings of this study therefore suggest that it would be beneficial to 
review the provision of lifestyle advice to patients attending an AMD outpatients’ clinic, and to 
consider whether advice is being provided in an optimal format.  
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APPENDIX 1 
No. Question Response Options 
1 What is your age in years? Specify years 
2 Are you… Male/Female 
3 Which of the following best describes your living 
arrangements? 
I live alone; I live with relative/ partner/ friend/ carer; 
I live in a nursing home  
Other (please specify)  
4 How long ago were you diagnosed with age-related 
macular degeneration? 
Within the last year; 1-2 years ago; 2-5 years ago; >5 
years ago  
5. Who first detected your age-related macular 
degeneration?  
High Street Optometrist; Hospital Eye Care 
Practitioner; GP; Don’t remember; Other (please 
specify)  
6. What dietary recommendations were made to you by 
your hospital eyecare practitioner with respect to your 
eye condition? (tick all that apply) 
None; Eat plenty of green leafy vegetables; Eat more 
oily fish; Eat lots of different coloured fruits and 
vegetables; Cut down on saturated fats; Eat a 
balanced diet; Reduce alcohol intake; Don’t 
remember; Other (please specify)  
7.  Have you received advice on your diet from any sources 
outside of the hospital with respect to your eye 
condition? (tick all that apply; summarise advice given) 
High street Optometrist; Internet; Macular Society / 
RNIB / Other voluntary organisation; GP 
8. Have you made any changes to your diet since being 
diagnosed with age-related macular degeneration, based 
on this advice? 
No (go to Qu 9); Yes (please describe the changes you 
have made)  
9. If you did not make changes to your diet, what was/were 
the reason(s)? (tick all that apply) 
I hadn’t been given any advice to change my diet; I 
didn’t understand how it would help my eyes; Too 
expensive; My diet is already good; I/my 
family/partner don’t like the foods recommended; 
Too much else to worry about / too much hassle; 
Other reason (please specify) 
10 Did your hospital eyecare practitioner recommend that 
you take a daily nutritional supplement? (e.g. vitamins, 
minerals etc) 
Yes/No 
11. Have you received advice to take daily nutritional 
supplements from any other sources with respect to 
your eye condition? (tick all that apply; summarise advice 
given) 
No; High street Optometrist; Internet;  
Macular Society / RNIB / Other voluntary 
organisation; GP; Newspaper / magazine; Friend / 
relative; Other (please specify)  
12.  Have you started taking daily nutritional supplements as 
a result of your eye condition? 
Yes (go to Qu 13); No (go to Qu 14) 
13.  If you have started taking daily nutritional supplements 
as a result of your eye condition, which are you taking? 
(tick all that apply) 
Bausch & Lomb Preservision; Bausch & Lomb 
Preservision AREDS2; Macushield; ICaps; Bausch & 
Lomb Ocuvite; VisiVite; Not sure; Other(s) (please 
specify) 
14.  
 
If you did not start taking daily nutritional supplements, 
what was/were the reason(s)? (all that apply) 
I hadn’t been given any advice to do so; I forgot the 
advice; I didn’t understand how it would help my 
eyes; Too expensive; I have a balanced diet; I am 
worried about the potential side effects; I wasn’t sure 
which one to take; I have too many other 
medications to take; Other (please specify) 
15 Do you smoke cigarettes? Yes (go to Qu 16); Not now, but I did in the past (go 
to Qu 19); No, never (go to Qu 20) 
16 If you are a current smoker, please could you answer the 
following: How many cigarettes do you smoke, on 
average, per day? For how many years have you 
smoked? 
Specify number of cigarettes; Specify number of 
years smoked 
17 If you are a current smoker, did your hospital eyecare Yes/No/can’t remember 
19 
 
practitioner advise you to stop smoking when you were 
diagnosed with age-related macular degeneration? 
18 If you are a current smoker, and your hospital eyecare 
practitioner did advise you to stop smoking, what were 
your reasons for not stopping? 
I enjoy smoking; I don’t see how it will help my eyes; 
It’s too difficult to stop; Other (please specify) 
19 If you used to smoke cigarettes but have given up, please 
could you answer the following: How many cigarettes did 
you used to smoke, on average, per day? For how many 
years did you smoke? Did you stop smoking because of 
your eye condition? 
Specify number of cigarettes; Specify number of 
years smoked; Yes/no 
20. Other than verbal advice and information, were you 
provided with any of the following by your hospital 
eyecare practitioner? (tick all that apply) 
An information sheet / leaflet about lifestyle changes; 
Information about support groups, such as the 
Macular Society; An information sheet / leaflet about 
your eye condition 
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